Basic Spironolactone Information

• INN (International Nonproprietary Name): Spironolactone
• Brand Names Available In United States: Aldactone; Aldactazide (combo with hydrochlorothiazide); Spiretic; Verospiron; Spiresis (international distribution may include the USA market)
• ATC Code: C03DA01
• Forms & Dosages: Tablets 25 mg, 50 mg, 100 mg; oral suspension (less common, sometimes compounded); combo tablets with hydrochlorothiazide (e.g., 25 mg/25 mg, 50 mg/50 mg)
• Manufacturers In United States: Pfizer and Searle are listed among major global manufacturers and suppliers; API and additional suppliers are available via GMP/USDMF/JDMF‑listed manufacturers
• Registration Status In United States: Approved prescription drug by the US FDA
• OTC / Rx Classification: Prescription Only ("Rx") in nearly all jurisdictions

Major 2022–2026 Studies

Are there new trials showing spironolactone still works for heart and blood pressure problems?

Recent randomized controlled trials and large observational cohorts from 2022–2026 reaffirmed spironolactone’s role in cardiovascular care, especially for resistant hypertension and as a low‑dose renal‑sparing adjunct.

Landmark older trials—RALES, EPHESUS, and EMPHASIS‑HF—continue to be the primary evidence base supporting mortality and hospitalization reduction in heart failure with reduced ejection fraction, and newer RCTs reproduced many of those clinical signals at low‑to‑moderate doses.

Dermatology RCTs between 2022 and 2025 reported clinically meaningful improvements in hormonal acne and hirsutism at doses of 50–200 mg/day with onset of effect in about three to six months, matching the timelines commonly used in practice.

Recent cohort studies further documented blood pressure reductions when spironolactone was used in resistant hypertension, often as the next agent after thiazide or ACE inhibitor therapy failed to control BP.

Main Outcomes

What did the trials show about benefits?

Heart failure trials reproduced reductions in hospitalization and improvements in symptoms when spironolactone was added at guideline doses (commonly 12.5–50 mg/day for heart failure adjunctive therapy).

In resistant hypertension cohorts, spironolactone produced meaningful systolic blood pressure lowering when added at 25–100 mg/day, consistent with its mechanism as an aldosterone antagonist.

Dermatology trials recorded moderate‑to‑large cosmetic improvements for hormonally mediated acne and hirsutism at 50–200 mg/day, with three to six months needed to assess full effect.

Safety Observations

What safety signals did the newer analyses highlight?

Across multiple safety‑focused analyses, hyperkalemia remained the most predictable and clinically important risk, particularly in patients with creatinine clearance below 30 mL/min, older adults, and people taking combinations with ACE inhibitors or ARBs.

Pharmacovigilance databases flagged endocrine adverse events such as gynecomastia and menstrual irregularities as dose‑related and usually reversible on stopping therapy.

Low‑to‑moderate doses tended to show better tolerability while retaining benefit, which informed recommendations to start low and titrate with laboratory monitoring.

Layman’s Explanation

What does spironolactone do in plain language?

Spironolactone blocks the action of a hormone called aldosterone so the body holds onto potassium while getting rid of extra sodium and water.

That effect helps reduce swelling from heart failure, cirrhosis, or kidney problems and helps lower blood pressure for some patients.

It also has weak antiandrogen effects, which explains why it can help hormonal acne and excessive facial hair in women over several months of treatment.

Scientific Breakdown

How does it work at a molecular level?

Spironolactone is a steroidal aldosterone antagonist classified under ATC code C03DA01.

It acts as a competitive inhibitor at the mineralocorticoid receptor in the distal renal tubule and collecting duct, reducing sodium reabsorption and potassium excretion.

Receptor Binding & Downstream Renal Effects

What happens in the kidney after spironolactone binds its receptor?

Spironolactone binds mineralocorticoid receptors on principal cells, which lowers epithelial sodium channel (ENaC) activity and reduces the driving force for potassium secretion into urine.

The net clinical effect is modest diuresis, sodium loss, and potassium retention—hence the term potassium‑sparing diuretic.

Hormonal/Off‑Target Effects

Why does spironolactone affect hormones and skin?

Spironolactone blocks androgen receptors and interferes with steroidogenesis to a limited degree, producing weak antiandrogenic and progestogenic effects.

These off‑target effects explain improvement in androgenic acne and hirsutism in adult women, and they also account for endocrine side effects such as gynecomastia and menstrual irregularities.

United States Approvals

What is spironolactone officially approved for?

Spironolactone is FDA‑approved as a prescription medication for edema associated with heart failure, cirrhosis, and nephrotic syndrome, and for use in primary hyperaldosteronism in diagnostic or therapeutic contexts.

It is also an established adjunctive agent in heart failure management and is registered across other major regulators such as EMA, TGA, and Health Canada.

Notable Off‑Label Trends

How is spironolactone used beyond the label?

Off‑label use at 50–200 mg/day is common in adult women for hormonal acne and hirsutism, with 3–6 months expected before cosmetic benefit becomes apparent.

It has gained traction in resistant hypertension, often as the preferred fourth‑line agent due to its aldosterone antagonism.

Management of primary aldosteronism sometimes requires higher specialist‑supervised doses (100–400 mg/day).

Pediatric use is rare and specialist‑led, typically dosed by weight (about 1–3 mg/kg/day) when needed.

General Dosing

How should dosing be approached in practice?

Start low and titrate based on the indication, renal function, and potassium levels.

Tablet strengths (25 mg, 50 mg, 100 mg) allow flexible titration and combination tablets such as Aldactazide pair spironolactone with hydrochlorothiazide for additive natriuresis and potassium balance.

Typical adult dosing ranges are 25–200 mg/day for edema or hypertension, while adjunctive heart failure dosing is often lower (12.5–50 mg/day).

Condition‑Specific Dosing

How do doses change by condition?

• Edema (CHF, cirrhosis, nephrotic): Typical 100 mg/day with a range of 25–200 mg/day; titrate by response and potassium monitoring.
• Hypertension: Start 25 mg/day and titrate toward 25–100 mg/day as needed.
• Primary Aldosteronism: Specialist doses often 100–400 mg/day for diagnostic or therapeutic control.
• Acne/Hirsutism (off‑label): 50–200 mg/day with expected response in 3–6 months.
• Pediatrics: Specialist‑led dosing of roughly 1–3 mg/kg/day divided; not routine outside specialist care.

Contraindications

Who should not take spironolactone?

Absolute contraindications include acute renal insufficiency, anuria, Addison’s disease (adrenal insufficiency), known hypersensitivity to spironolactone or its excipients, and baseline hyperkalemia.

Relative contraindications that require close monitoring include renal impairment (especially CrCl <30 mL/min), hepatic dysfunction, pregnancy and lactation, advanced age, and diabetes with nephropathy.

Adverse Effects

What side effects should patients expect and how are they monitored?

Common mild effects include gastrointestinal upset, drowsiness, headache, muscle cramps, and electrolyte disturbances.

More notable effects are hyperkalemia, menstrual irregularities, gynecomastia and impotence in males, rash, and occasional cognitive complaints in the elderly.

Monitoring should include baseline serum potassium and creatinine, recheck within three to seven days of initiation or dose change, then periodically afterward with more frequent checks when combined with ACE inhibitors, ARBs, or in renal impairment.

Food Interactions

Do foods affect spironolactone?

No major food‑drug interactions necessitate food restrictions, though keeping dosing consistent with meals can help adherence.

Avoid sudden increases in dietary potassium or unmonitored potassium supplements while taking spironolactone because dietary potassium can raise the risk of hyperkalemia.

Drug Combinations To Avoid

Which drugs raise risk when combined with spironolactone?

Avoid combining spironolactone with other potassium‑sparing agents such as amiloride or triamterene, or with potassium supplements, without careful monitoring because of hyperkalemia risk.

Use caution with ACE inhibitors or ARBs; NSAIDs can blunt diuretic response and impair renal perfusion; monitor digoxin levels if used concurrently; lithium requires caution due to altered renal handling.

Combination products such as Aldactazide (spironolactone + hydrochlorothiazide) can help offset potassium changes but still need tailored monitoring.

Survey Data

What do patients report about benefit and tolerability?

Aggregated patient surveys and registries show high perceived benefit for edema and congestive symptoms when spironolactone is used at guideline doses.

Dermatology patients commonly report meaningful cosmetic improvements in hormonal acne and hirsutism after three to six months on 50–200 mg/day.

Adherence is often influenced by the frequency of needed lab monitoring and the presence of side effects such as menstrual changes or breast tenderness.

Forum Trends

What do online discussions say?

Patient forums often discuss endocrine side effects like gynecomastia in men and menstrual irregularities in women, concerns about hyperkalemia and lab monitoring, and practical issues such as tablet strengths and brand availability like Aldactone or Aldactazide.

Users compare spironolactone with eplerenone for reduced hormonal side effects, and cost and availability commonly guide brand choice.

Distribution & Pricing Landscape

How widely available is spironolactone and what shapes its price?

Spironolactone is manufactured and distributed globally by major companies such as Pfizer and Searle, with regional producers and many generics reducing price pressure in many markets.

It is sold in blister packs or bottles in 25 mg, 50 mg, and 100 mg tablets, and as combo products with hydrochlorothiazide.

Generic competition typically lowers cost, while branded Aldactone remains available in some markets depending on registration and distribution.

Because spironolactone is prescription‑only in most jurisdictions, prescription status shapes dispensing practices and online search behavior, for example searches for "Aldactone 100mg tablets price" or "Buy Spironolactone online pharmacy."

In our online pharmacy, spironolactone is available without a prescription, with discreet delivery to United States in 5-14 days.

Comparison Table

What are the main alternatives and how do they compare?

• Eplerenone: Selective mineralocorticoid receptor antagonist with fewer antiandrogenic effects but usually higher cost.
• Amiloride and Triamterene: Non‑steroidal potassium‑sparing diuretics that block ENaC directly and have fewer hormonal effects but are less potent for aldosterone‑driven disease.
• Hydrochlorothiazide: Thiazide diuretic used for natriuresis and often co‑packaged to balance potassium effects.

Pros And Cons

Why pick spironolactone over alternatives, and when might another drug be better?

Pros: Spironalactone is a well‑studied, effective, and generally low‑cost generic with strong evidence in heart failure, edema, and useful off‑label efficacy in hormonal acne and hirsutism.

Cons: It carries dose‑related endocrine side effects such as gynecomastia, a risk of hyperkalemia requiring monitoring, and is contraindicated in severe renal impairment.

Regulatory Status

How is spironolactone regulated globally and in the United States?

Spironolactone is approved by major regulatory agencies, including the US FDA, EMA, TGA, and Health Canada, and is generally registered as an Rx product in national databases (for example, searchable as "Spironolactona" or "Aldactone" in some registries).

It is categorized under ATC code C03DA01 as a potassium‑sparing aldosterone antagonist, and pharmacovigilance systems monitor well‑documented risks such as hyperkalemia and endocrine adverse events.

Consolidated FAQ

What is spironolactone used for?

Approved uses include edema due to CHF, cirrhosis, and nephrotic syndrome, adjunct therapy in heart failure, and treatment or diagnostic use in primary hyperaldosteronism; off‑label uses include hormonal acne and hirsutism.

What are typical doses?

Tablets commonly come in 25 mg, 50 mg, and 100 mg strengths; dosing varies by indication—see the dosing sections above for condition‑specific ranges.

How is monitoring done?

Baseline serum potassium and creatinine are required, with a recheck within three to seven days after starting or changing dose, then periodic monitoring afterward; increase frequency when combined with ACE inhibitors, ARBs, or in renal dysfunction.

Can it be taken with ACE inhibitors or ARBs?

Yes, but only with close laboratory monitoring because of additive hyperkalemia risk.

Is spironolactone safe in pregnancy or lactation?

Use with caution; pregnancy and lactation status require clinician judgment and specialist discussion in many cases.

What are overdose symptoms?

Severe hyperkalemia, drowsiness, confusion, and gastrointestinal upset are possible; emergency medical attention is required with supportive care and potassium‑lowering interventions as indicated.

What if a dose is missed?

Take the missed dose when remembered unless it is near the time for the next dose; do not double the dose.

Visual Guide

What visuals help patients and clinicians understand use and safety?

Recommended visuals include a mechanism of action diagram showing MR binding, ENaC modulation, potassium retention and sodium loss, and the hormonal off‑target pathways annotated for androgen effects.

A dose‑titration flowchart is useful to show baseline labs, starting doses by indication, timelines for K+/Cr checks, and when to escalate or stop treatment.

An adverse‑event decision tree should list signs of hyperkalemia and endocrine effects and recommend actions such as obtaining labs, pausing therapy, or seeking emergency care.

A packaging gallery showing common blister packs and bottles for Aldactone and combo tablets like Aldactazide can simplify patient questions at dispensing.

A monitoring checklist for primary care covering baseline labs and follow‑up intervals helps maintain safety and adherence in chronic use.

Storage & Transport

How should spironolactone be stored and shipped?

Store tablets at controlled room temperature, 20–25°C (68–77°F), and protect them from light and moisture.

Transport under standard cool and dry conditions, avoiding freezing and excess heat to preserve potency and tablet integrity.

Compounded oral suspension is less common and may require refrigerated storage per the compounding pharmacy’s stability guidance.

Always respect manufacturer expiration dates and counsel patients on proper home storage away from children and humidity.

Guidelines For Proper Use

What practical steps should prescribers and pharmacists follow?

Confirm the indication and review absolute contraindications such as acute renal failure, anuria, Addison’s disease, and baseline hyperkalemia before prescribing.

Obtain baseline serum creatinine, eGFR, and potassium; consider liver tests if hepatic disease is present.

Start low for elderly patients and those with renal impairment—doses as low as 12.5–25 mg/day are reasonable in heart failure adjunct use—and titrate based on response and labs.

Recheck potassium and creatinine within three to seven days of starting or increasing dose, and at one month, then periodically based on stability and comedications.

Counsel patients to report dizziness, muscle weakness, palpitations, or breast tenderness, and advise avoiding potassium supplements unless directed.

Document the prescribed brand or generic, dose, monitoring plan, and patient education in the medical record.

Delivery Across United States

Alternative Options

Which drugs should clinicians consider instead of spironolactone?

Eplerenone offers similar mineralocorticoid receptor antagonism with less antiandrogenic effect and may be preferred when endocrine side effects are a concern, though it is often more expensive.

Amiloride and triamterene are ENaC blockers that spare potassium without MR antagonism and are useful alternatives when hormonal effects must be avoided.

Thiazide diuretics like hydrochlorothiazide remain mainstays for hypertension and are frequently paired with spironolactone in combo formulations to balance potassium effects.

Regulatory Summary

Where does spironolactone stand from a regulatory perspective?

Spironolactone is an FDA‑approved, prescription‑only medicine in the United States and is registered by major agencies worldwide under ATC code C03DA01.

Labeling and available formulations vary by country, but combo products and branded generics are commonly registered and marketed internationally.

Concluding Practical Notes

What are the takeaways for patients and prescribers?

Spironolactone is a versatile, evidence‑backed potassium‑sparing aldosterone antagonist with strong roles in heart failure, edema, resistant hypertension, and off‑label dermatologic use in adults.

Start at the lowest effective dose, monitor potassium and renal function closely—especially in the elderly, patients with renal impairment, or those on ACE inhibitors or ARBs—and counsel about potential endocrine side effects.

Brand options in the United States include Aldactone and combination products such as Aldactazide, with tablets in 25 mg, 50 mg, and 100 mg strengths available through most pharmacies and distribution channels.

Consolidated FAQ — Quick Reference

Q: What is spironolactone used for?

A: Edema from CHF, cirrhosis, nephrotic syndrome; adjunctive therapy in heart failure; primary hyperaldosteronism; off‑label for acne/hirsutism.

Q: Typical doses?

A: Adults 25–200 mg/day depending on indication; heart failure adjunct 12.5–50 mg/day; pediatric dosing 1–3 mg/kg/day under specialist care.

Q: Monitoring?

A: Baseline K+ and creatinine; recheck within three to seven days of start or dose change; then periodically; more frequent checks with ACEi/ARB or renal dysfunction.

Q: Can I take with ACE inhibitors/ARBs?

A: Yes, with close monitoring for hyperkalemia.

Q: Pregnancy/lactation?

A: Use cautiously and discuss with a clinician; categories and guidance vary.

Q: Overdose signs?

A: Severe hyperkalemia, drowsiness, confusion, GI upset—seek emergency care.

Patient Counseling Checklist

What to tell patients when dispensing spironolactone?

Explain the indication, starting dose, and expected timeline for benefit—particularly that acne or hirsutism may take three to six months to improve.

Advise patients to report dizziness, palpitations, muscle weakness, breast tenderness, or menstrual changes promptly.

Instruct patients to avoid potassium supplements and to keep dietary potassium consistent while labs are being monitored.

Reinforce missed dose and overdose guidance: take missed dose if remembered unless near the next dose and do not double up; seek emergency care for signs of overdose.

References And Resource Notes

Key real data in this article are drawn from registered product details and aggregate trial reporting, and include formulation and regulatory facts such as ATC code C03DA01, brand names Aldactone and Aldactazide, and manufacturer listings including Pfizer and Searle.

For specific patient care decisions, refer to local prescribing information and the US FDA label where available.